IP Verse

Incyte competitive analysis

Latest publications and patents of Incyte New

Explore the latest publications and patents granted to Incyte, showcasing their recent innovations and technological advancements.

Last updated on: Oct 2, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Incyte

EP3272738
Nov 13, 2024Processes For Preparing Jak Inhibitors And Related Intermediate CompoundsGranted And Under Opposition
EP3773593
May 15, 2024Treatment Of Hidradenitis Suppurativa Using Jak InhibitorsGranted And Under Opposition
EP2919766
May 26, 2021Sustained-Release Dosage Forms Of RuxolitinibGranted And Under Opposition
EP3070090
Dec 12, 2018Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- CyclopentylpropanenitrileRevoked
EP3184526
Oct 3, 2018Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase InhibitorGranted And Under Opposition
EP2671882
Feb 21, 2018Pyrrolo[2,3-B]Pyridin-4-Yl-Amines And Pyrrolo[2M3-B]Pyrimidin-4-Yl-Amines As Janus Kinase InhibitorsOpposition Rejected
EP3050882
Jan 31, 2018Piperidin-4-Yl Azetidine Derivatives As Jak1 InhibitorsRevoked
EP2300455
Jul 19, 2017Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl) - Imidazo [1, 2-B] [1, 2, 4] Triazin-2-Yl] Benzamide And Processes Related To Preparing The SameOpposition Rejected

Latest oppositions filed by Incyte

Explore patent oppositions filed by Incyte against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 9, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3450434
Deuterated Derivatives Of RuxolitinibCONCERT PHARMACEUTICALSNov 23, 2021

Latest patents of Incyte opposed by its competitors

Explore Incyte's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 9, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3272738
Nov 13, 2024Processes For Preparing Jak Inhibitors And Related Intermediate Compounds2
EP3773593
May 15, 2024Treatment Of Hidradenitis Suppurativa Using Jak Inhibitors1
EP2919766
May 26, 2021Sustained-Release Dosage Forms Of Ruxolitinib4
EP3070090
Dec 12, 2018Use Of Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H- Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile1
EP3184526
Oct 3, 2018Pyrrolo[2,3-D]Pyrimidine Derivatives As Janus Kinase Inhibitor1
EP2671882
Feb 21, 2018Pyrrolo[2,3-B]Pyridin-4-Yl-Amines And Pyrrolo[2M3-B]Pyrimidin-4-Yl-Amines As Janus Kinase Inhibitors1
EP3050882
Jan 31, 2018Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors1
EP2300455
Jul 19, 2017Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl) - Imidazo [1, 2-B] [1, 2, 4] Triazin-2-Yl] Benzamide And Processes Related To Preparing The Same1

Latest PTAB cases involving Incyte

Discover the latest PTAB cases involving Incyte, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 8, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Incyte

PGR2021-00006Oct 28, 2020INCYTECONCERT PHARMACEUTICALSFinal Written Decision
PGR2017-00034Jun 27, 2017CONCERT PHARMACEUTICALSINCYTEInstitution Denied
IPR2017-01256Apr 7, 2017INCYTECONCERT PHARMACEUTICALSFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Incyte with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 9, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
INCYTE11221Defensive
ALFRED E TIEFENBACHER443 - - Highly Aggressive
CONCERT PHARMACEUTICALS2112Aggressive
GENERICS UK212 - - - Highly Aggressive